| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Smooth, Vascular | 18 | 2019 | 317 | 3.450 |
Why?
|
| Bradykinin | 24 | 2015 | 157 | 3.260 |
Why?
|
| Receptor, Bradykinin B2 | 13 | 2019 | 75 | 2.410 |
Why?
|
| Kallikreins | 24 | 2020 | 323 | 2.020 |
Why?
|
| Kidney | 23 | 2017 | 945 | 1.910 |
Why?
|
| Diabetes Mellitus, Experimental | 18 | 2013 | 195 | 1.690 |
Why?
|
| Connective Tissue Growth Factor | 11 | 2018 | 76 | 1.650 |
Why?
|
| Diabetic Nephropathies | 11 | 2015 | 161 | 1.540 |
Why?
|
| Rats | 51 | 2019 | 5300 | 1.290 |
Why?
|
| Aorta | 12 | 2019 | 316 | 1.250 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2020 | 529 | 1.240 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2019 | 144 | 1.140 |
Why?
|
| Models, Statistical | 2 | 2021 | 448 | 1.110 |
Why?
|
| Rats, Sprague-Dawley | 29 | 2019 | 2083 | 1.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 7 | 2010 | 146 | 1.050 |
Why?
|
| Cells, Cultured | 25 | 2019 | 2673 | 1.030 |
Why?
|
| Immediate-Early Proteins | 6 | 2008 | 63 | 1.010 |
Why?
|
| MAP Kinase Signaling System | 6 | 2019 | 247 | 0.980 |
Why?
|
| Lipoproteins, LDL | 5 | 2012 | 343 | 0.960 |
Why?
|
| Prekallikrein | 6 | 2015 | 66 | 0.920 |
Why?
|
| Receptors, Bradykinin | 7 | 2018 | 50 | 0.870 |
Why?
|
| Glomerular Mesangium | 5 | 2005 | 53 | 0.860 |
Why?
|
| Angiotensin II | 7 | 2015 | 220 | 0.850 |
Why?
|
| Glucose | 6 | 2014 | 307 | 0.850 |
Why?
|
| Transcriptional Activation | 5 | 2015 | 226 | 0.810 |
Why?
|
| Animals | 66 | 2019 | 20881 | 0.810 |
Why?
|
| Patient Dropouts | 1 | 2021 | 98 | 0.750 |
Why?
|
| Up-Regulation | 5 | 2015 | 682 | 0.730 |
Why?
|
| Receptors, Thromboxane | 3 | 2019 | 122 | 0.710 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 7 | 2010 | 150 | 0.710 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 7 | 2010 | 147 | 0.700 |
Why?
|
| Protein Interaction Maps | 1 | 2019 | 30 | 0.660 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2010 | 110 | 0.660 |
Why?
|
| Signal Transduction | 17 | 2018 | 2689 | 0.660 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 6 | 2015 | 201 | 0.620 |
Why?
|
| Insulin | 13 | 2017 | 619 | 0.610 |
Why?
|
| Proteomics | 2 | 2017 | 246 | 0.540 |
Why?
|
| Kinins | 8 | 2018 | 109 | 0.540 |
Why?
|
| Glomerular Filtration Rate | 11 | 2012 | 274 | 0.540 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 5 | 1999 | 107 | 0.530 |
Why?
|
| Membrane Proteins | 2 | 2019 | 617 | 0.500 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 114 | 0.500 |
Why?
|
| RNA, Messenger | 13 | 2015 | 1664 | 0.490 |
Why?
|
| Enzymes | 1 | 2014 | 25 | 0.480 |
Why?
|
| Hydantoins | 1 | 2014 | 5 | 0.470 |
Why?
|
| Podocytes | 1 | 2015 | 113 | 0.470 |
Why?
|
| Biosensing Techniques | 1 | 2014 | 51 | 0.470 |
Why?
|
| Enzyme Activation | 13 | 2015 | 791 | 0.450 |
Why?
|
| Antibodies | 1 | 2014 | 241 | 0.450 |
Why?
|
| Receptors, Lysosphingolipid | 3 | 2015 | 63 | 0.440 |
Why?
|
| Diabetic Angiopathies | 3 | 2015 | 203 | 0.440 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2013 | 80 | 0.440 |
Why?
|
| Male | 49 | 2020 | 37321 | 0.440 |
Why?
|
| Transforming Growth Factor beta | 4 | 2006 | 384 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-fos | 3 | 2010 | 114 | 0.420 |
Why?
|
| Mesangial Cells | 2 | 2012 | 37 | 0.420 |
Why?
|
| Tissue Engineering | 1 | 2014 | 212 | 0.420 |
Why?
|
| Calcium | 7 | 2015 | 929 | 0.420 |
Why?
|
| Epoprostenol | 2 | 2010 | 71 | 0.420 |
Why?
|
| Arrestins | 1 | 2013 | 92 | 0.420 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2005 | 250 | 0.390 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2019 | 282 | 0.390 |
Why?
|
| Reactive Oxygen Species | 4 | 2013 | 499 | 0.390 |
Why?
|
| Blood Glucose | 8 | 2017 | 631 | 0.380 |
Why?
|
| Computer Simulation | 3 | 2021 | 706 | 0.370 |
Why?
|
| Receptor, PAR-2 | 1 | 2010 | 7 | 0.370 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 498 | 0.370 |
Why?
|
| Receptor, PAR-1 | 1 | 2010 | 30 | 0.370 |
Why?
|
| Renin | 3 | 1997 | 96 | 0.360 |
Why?
|
| Cyclic AMP | 1 | 2010 | 223 | 0.340 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 138 | 0.330 |
Why?
|
| ErbB Receptors | 1 | 2010 | 239 | 0.320 |
Why?
|
| Gene Expression | 5 | 2004 | 770 | 0.320 |
Why?
|
| Phosphorylation | 9 | 2015 | 1200 | 0.310 |
Why?
|
| Gene Deletion | 2 | 2015 | 235 | 0.300 |
Why?
|
| Biomarkers | 3 | 2018 | 1593 | 0.290 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1054 | 0.290 |
Why?
|
| Kallikrein-Kinin System | 2 | 2018 | 18 | 0.280 |
Why?
|
| Cell Proliferation | 3 | 2014 | 1174 | 0.270 |
Why?
|
| Vasoconstrictor Agents | 3 | 2004 | 107 | 0.270 |
Why?
|
| Dietary Proteins | 4 | 1996 | 51 | 0.270 |
Why?
|
| Humans | 31 | 2021 | 68618 | 0.270 |
Why?
|
| Collagen Type IV | 1 | 2005 | 28 | 0.260 |
Why?
|
| Oxidative Stress | 4 | 2017 | 718 | 0.250 |
Why?
|
| HEK293 Cells | 4 | 2015 | 326 | 0.240 |
Why?
|
| Kidney Glomerulus | 2 | 2005 | 155 | 0.230 |
Why?
|
| Cytochrome P-450 CYP4A | 2 | 2013 | 6 | 0.230 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 2013 | 10 | 0.230 |
Why?
|
| Kidney Diseases | 1 | 2006 | 307 | 0.220 |
Why?
|
| Calmodulin | 2 | 2001 | 53 | 0.210 |
Why?
|
| Aprotinin | 4 | 1998 | 55 | 0.210 |
Why?
|
| Endothelial Cells | 1 | 2005 | 384 | 0.210 |
Why?
|
| RNA Interference | 5 | 2015 | 266 | 0.210 |
Why?
|
| Lysophospholipids | 4 | 2015 | 209 | 0.200 |
Why?
|
| Anemia, Sickle Cell | 1 | 2006 | 364 | 0.200 |
Why?
|
| Sphingosine | 4 | 2015 | 315 | 0.200 |
Why?
|
| Antioxidants | 1 | 2004 | 304 | 0.190 |
Why?
|
| Likelihood Functions | 1 | 2021 | 106 | 0.190 |
Why?
|
| Diabetic Foot | 1 | 2021 | 33 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 710 | 0.190 |
Why?
|
| Body Weight | 3 | 2017 | 554 | 0.180 |
Why?
|
| Hypertension | 2 | 2015 | 1535 | 0.180 |
Why?
|
| Protein Kinase C | 3 | 2011 | 270 | 0.170 |
Why?
|
| Renal Circulation | 9 | 1997 | 49 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1745 | 0.170 |
Why?
|
| Zymosan | 1 | 2019 | 12 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2017 | 38 | 0.170 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 40 | 0.170 |
Why?
|
| Gene Expression Regulation | 3 | 2005 | 1293 | 0.160 |
Why?
|
| Mice, Knockout | 4 | 2013 | 1692 | 0.160 |
Why?
|
| Protein Multimerization | 1 | 2019 | 71 | 0.160 |
Why?
|
| Peptide Fragments | 4 | 2008 | 483 | 0.160 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1998 | 48 | 0.160 |
Why?
|
| Blood Pressure | 6 | 2015 | 1451 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2021 | 254 | 0.160 |
Why?
|
| Cohort Studies | 5 | 2020 | 2358 | 0.160 |
Why?
|
| Enzyme Inhibitors | 4 | 2015 | 659 | 0.150 |
Why?
|
| NADPH Oxidases | 2 | 2015 | 80 | 0.150 |
Why?
|
| Blotting, Western | 3 | 2013 | 954 | 0.150 |
Why?
|
| Tubulin | 1 | 1997 | 60 | 0.150 |
Why?
|
| Kininogens | 1 | 2017 | 88 | 0.150 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 120 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 139 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 234 | 0.140 |
Why?
|
| Rats, Inbred Strains | 9 | 1992 | 532 | 0.140 |
Why?
|
| Hemodynamics | 6 | 2013 | 705 | 0.140 |
Why?
|
| Linear Models | 2 | 2015 | 521 | 0.140 |
Why?
|
| Endothelium, Vascular | 2 | 2013 | 371 | 0.140 |
Why?
|
| Streptozocin | 4 | 2013 | 34 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 142 | 0.140 |
Why?
|
| Cell Nucleus | 1 | 1997 | 305 | 0.140 |
Why?
|
| Receptor, Bradykinin B1 | 3 | 2015 | 25 | 0.140 |
Why?
|
| NADPH Oxidase 1 | 1 | 2015 | 1 | 0.130 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2015 | 19 | 0.130 |
Why?
|
| NADPH Oxidase 4 | 1 | 2015 | 17 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 3 | 2011 | 42 | 0.130 |
Why?
|
| Muscles | 1 | 1996 | 158 | 0.130 |
Why?
|
| Staurosporine | 1 | 2015 | 19 | 0.130 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2015 | 54 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1046 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 284 | 0.130 |
Why?
|
| Mice | 7 | 2019 | 8474 | 0.130 |
Why?
|
| Risk Factors | 6 | 2020 | 5731 | 0.130 |
Why?
|
| Albuminuria | 2 | 2008 | 171 | 0.120 |
Why?
|
| Calcium Channels | 1 | 2015 | 59 | 0.120 |
Why?
|
| Enzyme Precursors | 3 | 1990 | 27 | 0.120 |
Why?
|
| Transfection | 2 | 2015 | 782 | 0.120 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 175 | 0.120 |
Why?
|
| Losartan | 2 | 2013 | 45 | 0.120 |
Why?
|
| Quantum Dots | 1 | 2014 | 29 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 76 | 0.120 |
Why?
|
| Female | 15 | 2020 | 38074 | 0.120 |
Why?
|
| Protein Transport | 2 | 2012 | 280 | 0.120 |
Why?
|
| Cell Membrane | 2 | 2015 | 525 | 0.120 |
Why?
|
| Hydroxyl Radical | 1 | 2014 | 17 | 0.120 |
Why?
|
| Collagen Type I | 2 | 2005 | 175 | 0.120 |
Why?
|
| Adenosine | 1 | 2014 | 165 | 0.110 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2011 | 52 | 0.110 |
Why?
|
| Hydrogen Peroxide | 1 | 2014 | 168 | 0.110 |
Why?
|
| Time Factors | 5 | 2015 | 4655 | 0.110 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2013 | 4 | 0.110 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1993 | 8 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2012 | 376 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2013 | 17 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 331 | 0.110 |
Why?
|
| Nitric Oxide | 3 | 2013 | 382 | 0.110 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 62 | 0.110 |
Why?
|
| Allosteric Site | 1 | 2013 | 17 | 0.110 |
Why?
|
| Kinetics | 4 | 2001 | 1047 | 0.110 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2013 | 81 | 0.110 |
Why?
|
| Dimerization | 1 | 2013 | 99 | 0.110 |
Why?
|
| Enalapril | 1 | 1993 | 86 | 0.110 |
Why?
|
| Type C Phospholipases | 2 | 2011 | 67 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 940 | 0.110 |
Why?
|
| Aorta, Thoracic | 2 | 2013 | 211 | 0.110 |
Why?
|
| Bradykinin Receptor Antagonists | 4 | 1997 | 20 | 0.110 |
Why?
|
| Renin-Angiotensin System | 2 | 2007 | 79 | 0.100 |
Why?
|
| Virulence Factors, Bordetella | 3 | 2001 | 60 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 807 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2013 | 230 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2013 | 125 | 0.100 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 231 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 199 | 0.100 |
Why?
|
| Ligands | 1 | 2013 | 317 | 0.100 |
Why?
|
| Receptor, IGF Type 2 | 2 | 2011 | 13 | 0.100 |
Why?
|
| Amino Acids | 1 | 1992 | 131 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2002 | 82 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2012 | 137 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2012 | 246 | 0.100 |
Why?
|
| Cell Survival | 1 | 2014 | 901 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2012 | 98 | 0.090 |
Why?
|
| Receptors, Thrombin | 1 | 2010 | 18 | 0.090 |
Why?
|
| ADAM17 Protein | 1 | 2010 | 28 | 0.090 |
Why?
|
| Cholera Toxin | 2 | 2001 | 30 | 0.090 |
Why?
|
| EGF Family of Proteins | 1 | 2010 | 17 | 0.090 |
Why?
|
| Amphiregulin | 1 | 2010 | 19 | 0.090 |
Why?
|
| Flavonoids | 2 | 2001 | 109 | 0.090 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2010 | 7 | 0.090 |
Why?
|
| Blotting, Northern | 3 | 1996 | 189 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2010 | 53 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 434 | 0.090 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2010 | 73 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2010 | 694 | 0.090 |
Why?
|
| Macrophages | 3 | 2019 | 647 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2013 | 126 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2001 | 195 | 0.080 |
Why?
|
| Tyrosine | 3 | 1999 | 196 | 0.080 |
Why?
|
| Neurons | 1 | 2015 | 881 | 0.080 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2007 | 31 | 0.080 |
Why?
|
| Collagen | 2 | 2004 | 636 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2010 | 238 | 0.080 |
Why?
|
| Adolescent | 4 | 2015 | 8912 | 0.080 |
Why?
|
| Cell Movement | 2 | 2019 | 630 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1085 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 1990 | 222 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 615 | 0.080 |
Why?
|
| Colon | 1 | 1989 | 168 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2001 | 562 | 0.080 |
Why?
|
| Carotid Arteries | 1 | 2008 | 110 | 0.080 |
Why?
|
| Maleimides | 2 | 2011 | 15 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 1995 | 1447 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 839 | 0.070 |
Why?
|
| Protein Kinase C beta | 2 | 2011 | 19 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 627 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 104 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2008 | 179 | 0.070 |
Why?
|
| Osmolar Concentration | 2 | 2000 | 134 | 0.070 |
Why?
|
| Dinoprostone | 3 | 1997 | 110 | 0.070 |
Why?
|
| Base Sequence | 3 | 2010 | 1015 | 0.070 |
Why?
|
| Somatomedins | 1 | 2006 | 16 | 0.070 |
Why?
|
| Indoles | 2 | 2011 | 146 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2015 | 867 | 0.070 |
Why?
|
| Pancreatic Juice | 1 | 1986 | 9 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 77 | 0.070 |
Why?
|
| Captopril | 1 | 1986 | 22 | 0.070 |
Why?
|
| Albumins | 1 | 2006 | 72 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2006 | 120 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 1998 | 1174 | 0.060 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 2005 | 1 | 0.060 |
Why?
|
| Collagen Type II | 1 | 2005 | 13 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2005 | 56 | 0.060 |
Why?
|
| Reference Values | 5 | 1996 | 579 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2005 | 251 | 0.060 |
Why?
|
| Pancreas | 1 | 1986 | 225 | 0.060 |
Why?
|
| Thrombosis | 1 | 2006 | 218 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2006 | 204 | 0.060 |
Why?
|
| Isoenzymes | 2 | 2001 | 308 | 0.060 |
Why?
|
| Extracellular Fluid | 1 | 2004 | 29 | 0.060 |
Why?
|
| Cell Division | 3 | 2000 | 541 | 0.060 |
Why?
|
| Adult | 8 | 2020 | 21403 | 0.060 |
Why?
|
| RNA | 1 | 2005 | 171 | 0.060 |
Why?
|
| Oligonucleotide Probes | 2 | 1994 | 35 | 0.060 |
Why?
|
| Heparin | 2 | 2021 | 205 | 0.060 |
Why?
|
| Proteins | 1 | 2007 | 474 | 0.060 |
Why?
|
| Vasodilation | 2 | 1995 | 85 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 362 | 0.060 |
Why?
|
| Kininogen, High-Molecular-Weight | 1 | 2003 | 23 | 0.050 |
Why?
|
| Factor XII | 1 | 2003 | 96 | 0.050 |
Why?
|
| Actins | 2 | 1996 | 249 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 2550 | 0.050 |
Why?
|
| Oleic Acid | 2 | 2001 | 40 | 0.050 |
Why?
|
| Sex Factors | 1 | 2006 | 1266 | 0.050 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2001 | 42 | 0.050 |
Why?
|
| Emulsions | 1 | 2021 | 10 | 0.050 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2001 | 18 | 0.050 |
Why?
|
| Sulfates | 1 | 2021 | 28 | 0.050 |
Why?
|
| Alginates | 1 | 2021 | 35 | 0.050 |
Why?
|
| Veins | 1 | 2001 | 68 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2001 | 86 | 0.050 |
Why?
|
| Polyesters | 1 | 2021 | 55 | 0.050 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2001 | 28 | 0.050 |
Why?
|
| Hand | 1 | 2001 | 90 | 0.050 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2001 | 43 | 0.050 |
Why?
|
| Sodium | 3 | 2001 | 161 | 0.050 |
Why?
|
| Hyperglycemia | 2 | 2001 | 158 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2000 | 59 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 1996 | 202 | 0.050 |
Why?
|
| Young Adult | 3 | 2020 | 5717 | 0.050 |
Why?
|
| Shock, Septic | 1 | 2001 | 101 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2001 | 181 | 0.050 |
Why?
|
| src-Family Kinases | 1 | 2000 | 91 | 0.040 |
Why?
|
| Glycosylation | 1 | 2000 | 185 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2001 | 190 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2001 | 178 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2000 | 119 | 0.040 |
Why?
|
| Radioimmunoassay | 3 | 2002 | 164 | 0.040 |
Why?
|
| Protoporphyrins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Wound Healing | 1 | 2021 | 260 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 2279 | 0.040 |
Why?
|
| Metalloporphyrins | 1 | 2019 | 25 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2000 | 567 | 0.040 |
Why?
|
| Cytoplasm | 1 | 1999 | 155 | 0.040 |
Why?
|
| Fibrosis | 1 | 2000 | 371 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2011 | 200 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 455 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 411 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 1999 | 94 | 0.040 |
Why?
|
| Pharmaceutic Aids | 1 | 1998 | 7 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 1 | 1999 | 175 | 0.040 |
Why?
|
| Monocytes | 1 | 2019 | 210 | 0.040 |
Why?
|
| Neutrophils | 1 | 2019 | 204 | 0.040 |
Why?
|
| Phosphotyrosine | 1 | 1997 | 41 | 0.040 |
Why?
|
| Cyclic GMP | 2 | 1996 | 99 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 2791 | 0.040 |
Why?
|
| Vascular Resistance | 2 | 1996 | 179 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 82 | 0.040 |
Why?
|
| Cell Line | 4 | 2007 | 1752 | 0.040 |
Why?
|
| Cytosol | 1 | 1997 | 123 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1997 | 84 | 0.040 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1997 | 64 | 0.040 |
Why?
|
| Heart | 1 | 2002 | 850 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 1997 | 337 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2011 | 138 | 0.030 |
Why?
|
| Dogs | 4 | 2002 | 490 | 0.030 |
Why?
|
| Diet, Protein-Restricted | 1 | 1996 | 4 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1996 | 48 | 0.030 |
Why?
|
| Enalaprilat | 1 | 1996 | 4 | 0.030 |
Why?
|
| Glycogen | 1 | 1996 | 27 | 0.030 |
Why?
|
| Hypertension, Renovascular | 1 | 1996 | 47 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 792 | 0.030 |
Why?
|
| Myocardium | 1 | 2002 | 1204 | 0.030 |
Why?
|
| PC12 Cells | 1 | 2015 | 36 | 0.030 |
Why?
|
| Child | 1 | 2006 | 6405 | 0.030 |
Why?
|
| Peptides | 2 | 2002 | 455 | 0.030 |
Why?
|
| Cell Death | 1 | 2015 | 329 | 0.030 |
Why?
|
| Cholesterol | 1 | 2015 | 331 | 0.030 |
Why?
|
| Sodium, Dietary | 1 | 1993 | 31 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 16 | 0.030 |
Why?
|
| Microdialysis | 3 | 2002 | 147 | 0.030 |
Why?
|
| Prostaglandins H | 1 | 1993 | 32 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 45 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2013 | 89 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2013 | 94 | 0.030 |
Why?
|
| Receptors, Prostaglandin | 1 | 1993 | 74 | 0.030 |
Why?
|
| Leukocytes | 1 | 2013 | 99 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 1083 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 1030 | 0.030 |
Why?
|
| Eicosanoids | 1 | 1992 | 16 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 118 | 0.030 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1992 | 31 | 0.030 |
Why?
|
| Cattle | 1 | 2013 | 475 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 102 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2013 | 324 | 0.030 |
Why?
|
| Kidney Tubules | 1 | 1992 | 80 | 0.030 |
Why?
|
| Enzyme Activators | 1 | 2011 | 14 | 0.020 |
Why?
|
| Diglycerides | 1 | 2011 | 49 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3259 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 196 | 0.020 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 1990 | 3 | 0.020 |
Why?
|
| Smad1 Protein | 1 | 2010 | 10 | 0.020 |
Why?
|
| Veterans | 1 | 2018 | 904 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1330 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3705 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 207 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 159 | 0.020 |
Why?
|
| Sweat | 1 | 1989 | 5 | 0.020 |
Why?
|
| Indomethacin | 2 | 2001 | 107 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2002 | 155 | 0.020 |
Why?
|
| Methionine | 1 | 1989 | 36 | 0.020 |
Why?
|
| Iodohippuric Acid | 1 | 1988 | 1 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 536 | 0.020 |
Why?
|
| Edetic Acid | 1 | 1988 | 29 | 0.020 |
Why?
|
| Imidazoles | 2 | 2002 | 175 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 1989 | 117 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 786 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1990 | 511 | 0.020 |
Why?
|
| Iodine Radioisotopes | 2 | 2002 | 119 | 0.020 |
Why?
|
| Diet, Atherogenic | 1 | 2006 | 6 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 786 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2006 | 3 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2006 | 72 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2001 | 765 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 322 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1986 | 234 | 0.020 |
Why?
|
| Extracellular Space | 2 | 1996 | 121 | 0.020 |
Why?
|
| Submandibular Gland | 1 | 1984 | 34 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 447 | 0.020 |
Why?
|
| Swine | 1 | 1986 | 672 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 21147 | 0.010 |
Why?
|
| Angiotensin I | 1 | 2002 | 24 | 0.010 |
Why?
|
| Stearic Acids | 1 | 2001 | 6 | 0.010 |
Why?
|
| Linoleic Acid | 1 | 2001 | 13 | 0.010 |
Why?
|
| Oleic Acids | 1 | 2001 | 40 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 2001 | 108 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 2001 | 24 | 0.010 |
Why?
|
| Kidney Medulla | 1 | 2001 | 17 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2001 | 72 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2001 | 40 | 0.010 |
Why?
|
| Phenylephrine | 1 | 2001 | 61 | 0.010 |
Why?
|
| Lung | 1 | 1986 | 849 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2001 | 210 | 0.010 |
Why?
|
| Pyridines | 1 | 2002 | 261 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2001 | 618 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1999 | 137 | 0.010 |
Why?
|
| Rabbits | 1 | 1999 | 509 | 0.010 |
Why?
|
| Heart Rate | 1 | 2001 | 568 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 48 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 1033 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 248 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 140 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 134 | 0.010 |
Why?
|
| Genes, jun | 1 | 1997 | 13 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1998 | 260 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1997 | 109 | 0.010 |
Why?
|
| Research | 1 | 1998 | 214 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 1997 | 14 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1998 | 249 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 1998 | 241 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 981 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1999 | 434 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1997 | 289 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1997 | 223 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1996 | 152 | 0.010 |
Why?
|
| Biphenyl Compounds | 1 | 1996 | 184 | 0.010 |
Why?
|
| Tetrazoles | 1 | 1996 | 160 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1996 | 304 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 168 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1996 | 371 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1997 | 240 | 0.010 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1993 | 41 | 0.010 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 1993 | 52 | 0.010 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 1993 | 48 | 0.010 |
Why?
|
| Thromboxanes | 1 | 1992 | 53 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1992 | 65 | 0.010 |
Why?
|
| Caseins | 1 | 1992 | 19 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1993 | 284 | 0.010 |
Why?
|
| South Carolina | 1 | 1998 | 2752 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1992 | 1040 | 0.010 |
Why?
|
| Chromium Radioisotopes | 1 | 1988 | 11 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1989 | 75 | 0.000 |
Why?
|
| Alloxan | 1 | 1984 | 3 | 0.000 |
Why?
|